Landauer (NYSE: LDR) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical equipment, supplies & distribution – nec companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Landauer and Cytori Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Landauer 16.55% 96.20% 13.62%
Cytori Therapeutics -367.33% -228.21% -69.19%

Volatility & Risk

Landauer has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.

Valuation and Earnings

This table compares Landauer and Cytori Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Landauer N/A N/A N/A $1.92 35.00
Cytori Therapeutics $4.66 million 2.26 -$22.04 million ($0.90) -0.33

Landauer has higher earnings, but lower revenue than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than Landauer, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.6% of Landauer shares are held by institutional investors. Comparatively, 7.4% of Cytori Therapeutics shares are held by institutional investors. 6.6% of Landauer shares are held by insiders. Comparatively, 1.9% of Cytori Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dividends

Landauer pays an annual dividend of $1.10 per share and has a dividend yield of 1.6%. Cytori Therapeutics does not pay a dividend. Landauer pays out 57.3% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Landauer and Cytori Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landauer 0 1 0 0 2.00
Cytori Therapeutics 0 1 1 0 2.50

Cytori Therapeutics has a consensus target price of $3.65, indicating a potential upside of 1,116.67%. Given Cytori Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cytori Therapeutics is more favorable than Landauer.

Summary

Landauer beats Cytori Therapeutics on 8 of the 14 factors compared between the two stocks.

Landauer Company Profile

Landauer, Inc. is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products. The Company provides radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Medical physics services are provided through the Company’s Landauer Medical Physics (LMP) division. The Company uses LMP as a platform to expand into the medical physics services market, serving domestic hospitals, radiation therapy centers and imaging centers. The Company’s Medical Products segment provides medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Receive News & Ratings for Landauer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer and related companies with MarketBeat.com's FREE daily email newsletter.